Theravance Biopharma (TBPH) Retained Earnings (2014 - 2026)
Theravance Biopharma (TBPH) reported Retained Earnings of -$62000.0 for Q1 2026, up 99.99% year-over-year from -$31001.0 in Q1 2025, and up 99.99% quarter-over-quarter from -$859.6 million in Q4 2025.
Theravance Biopharma (TBPH) Retained Earnings (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 13 years of Retained Earnings data on file, last reported at -$62000.0 in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$62000.0, up 99.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$62000.0 (up 99.99% YoY), and the FY2025 annual result was -$859.6 million, up 10.97% from the prior year.
- Retained Earnings grew to -$62000.0 in Q1 2026 per TBPH's latest filing, from -$859.6 million in the prior quarter.
- Over five years, Retained Earnings peaked at $51000.0 in Q1 2023 and troughed at -$1.8 billion in Q1 2022.
- A 5-year average of -$429.5 million and a median of -$121000.0 in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings sank 10305917.65% in 2022, then surged 100.01% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$15000.0 in 2022, then tumbled by 333.33% to -$65000.0 in 2023, then tumbled by 1485318.46% to -$965.5 million in 2024, then advanced by 10.97% to -$859.6 million in 2025, then soared by 99.99% to -$62000.0 in 2026.
- Business Quant data shows TBPH's Retained Earnings at -$62000.0 in Q1 2026, -$859.6 million in Q4 2025, and -$920.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -838.07 Mn |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -62,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62,000.00 |
| Dec 31, 2025 | -859.63 Mn |
| Sep 30, 2025 | -920.65 Mn |
| Jun 30, 2025 | -924.27 Mn |
| Mar 31, 2025 | -979.10 Mn |
| Dec 31, 2024 | -965.52 Mn |
| Sep 30, 2024 | 50,000.00 |
| Jun 30, 2024 | -22,000.00 |
| Mar 31, 2024 | -41,000.00 |
| Dec 31, 2023 | -65,000.00 |
| Sep 30, 2023 | -900.59 Mn |
| Jun 30, 2023 | -286,000.00 |
| Mar 31, 2023 | 51,000.00 |
| Dec 31, 2022 | -15,000.00 |
| Sep 30, 2022 | -121,000.00 |
| Jun 30, 2022 | -45,000.00 |
| Mar 31, 2022 | -1.75 Bn |
| Dec 31, 2021 | -1.73 Bn |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | 8,000.00 |